Hematopoietic Stem Cell Transplantation for Combined Immunodeficiencies, on Behalf of IEWP-EBMT

Benedicte Neven and Francesca Ferrua

Combined immunodeficiencies (CID) are a clinically and genetically heterogeneous group of primary immunodeficiencies (PIDs) that affect T-lymphocyte immunity with abnormal development or function. As compared to severe combined immune deficiencies (SCID), these patients are usually diagnosed later. They display a broad infectious susceptibility; immune dysregulation manifestations and chronic lymphoproliferation are also frequent. These complications and their specific treatments can lead to persistent damage to several organs. Prognosis of CIDs is worse as compared to other PIDs. The curative treatment is usually hematopoietic stem cell transplantation (HSCT), but difficult questions remain regarding the definitive indication of HSCT and its timing; the final decision depends on a conjunction of factors such as immunological parameters, severity of clinical manifestations, and natural history of the disease, when molecular diagnosis is known. CD40L deficiency, a CID caused by mutations in CD40LG gene, well illustrates the dilemma between HSCT vs. long-term supportive treatment. This disease leads to higher risk of developing infections from bacterial and intracellular pathogens, especially Pneumocystis and Cryptosporidium spp. While supportive care allows improved survival during childhood, organ damages may develop with increasing age, mainly chronic lung disease and biliary tract disease (secondary to Cryptosporidium spp. infection) that may evolve later to sclerosing cholangitis, a severe complication associated with increased mortality. Early HSCT before organ damage development is associated with best survival and cure rate, while HSCT remains a risky therapeutic option for older patients, for those with organ damage, especially severe liver disease, and/or for those with limited or no donor availability. Prospective studies are needed to analyze risks of HSCT compared to those of life-long supportive therapy, including quality of life measures.

Keywords: HSCT, combined immunodeficiencies, decision to transplant, modalities and timing, CD40L
HETEROGENEITY OF COMBINED IMMUNODEFICIENCIES

Combined immunodeficiencies (CIDs) are a clinically and genetically heterogeneous group of primary immunodeficiencies (PIDs) that affect T-lymphocyte immunity with abnormal development or function. Humoral immunity may be intrinsically abnormal or defective as a consequence of an abnormal T-B lymphocyte cooperation (1).

Clinically, CIDs are extremely variable in terms of manifestations, age of onset and severity. A broad susceptibility to opportunistic and non-opportunistic infections including viruses, bacteria, protozoan and parasites is a hallmark of these diseases. Defects of immune regulation are frequent and can lead to autoimmune and immune dysregulation manifestations that in some circumstances can be the predominant features. They occur in up to 40% of patients with CIDs, autoimmune cytopenia and inflammatory bowel diseases being the most frequent (2). Chronic non-malignant lymphoproliferation can occur. It can lead to skin or visceral granulomatous lesions driven in some circumstances by persistent chronic infections such as vaccine-derived rubella virus (3). Increased susceptibility to malignancies, particularly lymphoma is observed (4). This can be due to impaired immunosurveillance to viral or tumoral antigens; chronic inflammation and infection with oncogenic viruses such as Epstein Barr Virus (EBV) can also promote lymphoproliferation. In some PIDs, intrinsic defects of DNA repair may further increase these oncogenic risks. Some CIDs can be associated with syndromic features as microcephaly, dysmorphic features, intrinsic growth retardation (related to osseous dysplasia) (5).

Infectious, autoimmune, inflammatory and oncogenic complications and their specific treatments can lead to persistent damage to several organs including lung, liver, digestive tract, and/or kidney.

There is a continuum between severe combined immune deficiencies (SCID) and CIDs without consensual demarcation between these two groups of diseases (6). CIDs differ by a later age of onset, later age at diagnosis, generally beyond the age of 1 year, and by a higher number of circulating T lymphocytes. Immunological abnormalities are highly variable from profound quantitative or qualitative abnormalities to significant residual T-lymphocyte immunity. Humoral immunity is variably affected. At the other end of the spectrum, common variable immune deficiency (CVID) that occurs later in life is predominately an antibody deficiency associated in some cases with an impaired T-cell immunity.

Molecular causes of CIDs are numerous and can affect either lymphopoiesis or T-lymphocyte function at several of the numerous developmental, activation or differentiation steps required for an efficient immune response (Table 1) (1). The international Union of Immunological Societies categorized and listed primary immunodeficiencies with known molecular causes (5) and more than 120 gene defects are responsible for CIDs.

Thanks to improved performance of next generation sequencing, there has been a rapid expansion in the identification of causative gene alterations among patients with CIDs in recent years. Genetic diagnostic is also shortened by these new approaches. However, a proportion of patients with CIDs remains without molecular diagnosis (37).

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CIDs

Indication to Transplant

Prognosis of CIDs is worse as compared to other PIDs such as humoral defects, innate, and granulocyte immune deficiencies (38). The curative treatment is often hematopoietic stem cell transplantation (HSCT) that has been increasingly successful in recent years. However, the broad spectrum of genetic defects underlying CIDs, the large range of T-cell defects and clinical heterogeneity in each disease make the decision about transplantation very challenging and prevent from universal recommendations regarding indication, timing and modalities of HSCT. Rather, it invites to disease and patient tailored treatment (39) that integrates and weights all these parameters including the characteristics of available donors to balance the final decision.

For patients with early severe clinical presentations mimicking SCID, the recommendation to drive the patient quickly to HSCT will be straightforward, including with alternative donors. However, no threshold of T-cell immunity required to prevent severe complications has been established. When molecular diagnosis is known, it may guide the decision for diseases with well-known natural history, helping to weight the balance between risks of disease evolution with potential development of future organ damage vs. risks of transplantation. However, many genetic causes of CIDs have been recently described, involving a small number of individuals with limited experiences, as summarized in Table 1. In these cases, natural history studies are needed. Several retrospective studies co-ordinated by the Inborn Error Working Party (IEWP) of the European Society for Bone and Marrow Transplantation (EBMT) are ongoing (e.g., in hypomorphic RAG1 and RAG2 deficiencies, CD27/CD70 deficiencies) and will help to define the best treatment strategies in these conditions. When the molecular diagnosis is unknown, the decision to proceed to transplant is mostly based on clinical judgement.

Retrospective studies performed in specific CIDs [Wiskott-Aldrich syndrome (WAS), MHCI expression deficiency, CD40L deficiency, dedicator of cytokinesis 8 (DOCK8) deficiency] (40–42) advocate for early transplantation before organ damage development or occurrence of severe, chronic infections [see reviews on Hematopoietic stem cell transplantation for WAS and DOCK8 deficiency (26) and for MHC class II expression deficiency]. Similar recommendations may apply more broadly to CIDs. The p-CID study, a prospective international multicentre observational study that is currently recruiting is designed to try to define clinical events and immunologic parameters predictive of outcome with the aim to help making the decision to transplant in these conditions (39).
### TABLE 1  | Non-exhaustive list of CID, their main clinical features and HSCT experiences.

| Genetic defects | Classification in Picard et al. (5) | Main clinical features | HSCT | References |
|-----------------|-------------------------------------|------------------------|------|------------|
| **Defects of T-cell production** | | | | |
| | Hypomorphic SCID (hypomorphic mutations of genes responsible for typical SCID) - mostly RAG1, RAG2. | Table 1 | CID with immune-dysregulation, autoimmunity, granuloma | Case reports | (7) |
| | Hypomorphic mutations in IL2RG and JAK3 genes | Table 1 | CID | Case reports | (8, 9) |
| | Defects of DNA repair, telomeropathies | Table 2 | See dedicated section | | |
| **Defects of Antigen presentation** | | | | |
| | Defects of MHC class II expression (RFXANK, CIITA, RFXAP, RFX5) | Table 1 | See dedicated section | | |
| | Defect of MHC class I expression (TAP1, TAP2, TAPBP, B2M) | Table 1 | Immune-dysregulation, granuloma | Case report | (10) |
| | TRAC (T-cell receptor alpha constant) | Table 1 | CID with immune-dysregulation | Case reports | (11) |
| | ZAP70 | Table 1 | CID with immune-dysregulation | Case reports | (12) |
| | ITK | Table 1 | CID - mainly EBV related diseases | Case reports | (13) |
| | LCK | Table 1 | CID with immune-dysregulation, auto-inflammation | Case report | (14) |
| | LAT | Table 1 | CID with immune-dysregulation, auto-immunity | Case report | (15) |
| | RHOH | Table 1 | CID - HPV infection | Case report | (16) |
| **Defects of T-cell activation** | Calcium signaling (STIM1, ORAI1) | Table 2 | CID with immune-dysregulation, autoimmunity | Case reports | (17) |
| | Magnesium signaling (MAGT1) | Table 1 | CID - EBV related diseases | Case reports | |
| | Hypomorphic mutation of IKBKG/IKK-gamma (NEMO) | Table 2 | CID with immune-dysregulation | Case reports | (18–20) |
| | Gain of function mutation in NIK (IkBa) | Table 2 | CID with immune-dysregulation | Case reports | |
| | CARMIL2 | Table 1 | CID with immune-dysregulation | Not reported | |
| | CBM signalosome complex (CARD11, BCL10, MALT1) | Table 1 | CID with immune-dysregulation | Case reports | (21) |
| | MAP3K14 (NIK) | Table 1 | CID | Case reports | (22) |
| | IKBKB (IKK2/IKK-beta) | Table 1 | CID | Case reports | (23) |
| **Defects of T-cell proliferation** | | | | |
| | CTPS1 | Table 1 | CID - EBV related diseases | Small series | (24) |
| **Defects of actin cytoskeleton** | WAS (WASP) | Table 2 | See dedicated section | Case reports | (25) |
| | WIPF1 (WIP) | Table 2 | CID with immune-dysregulation | Case reports | |
| | ARPC1B | Table 2 | CID with immune-dysregulation, autoimmunity | Case reports | |
| | DOCK8 | Table 1 | See dedicated section | Case reports | |
| | DOCK2 | Table 1 | CID with immune-dysregulation | Case reports | |
| | CORO1A (Coronin 1A) | Table 1 | CID - EBV related diseases | Case reports | (30, 31) |
| | MSN (Moesin) | Table 1 | CID, auto-immunity | Case reports | (32) |

(Continued)
| Genetic defects | Classification in Picard et al. (5) | Main clinical features | HSCT | References |
|----------------|-----------------------------------|------------------------|------|------------|
| RAC2 (dominant negative mutation) | Table 1 | Lymphopenia, defective neutrophil chemotaxis | Case reports | (33) |
| RAC2 (homozygous loss of function mutation) | Table 1 | CVID, autoimmunity | No HSCT reported | |
| RAC2 (gain of function mutations) | Table 1 | CID | Case reports | |
| CD27 | Table 4 | CID with immune dysregulation and EBV related diseases | Case reports | |
| CD70 | Table 4 | CID with immune dysregulation and EBV related disease | Case reports | |
| TNFRSF9 (4-1BB, CD137) | Table 4 | CID with immune dysregulation and EBV related disease | Case reports | |
| TNFRSF4 (OX40) | Table 1 | CID with HHV8-Kaposi sarcoma | No HSCT reported | |
| IL21-1L21R | Table 1 | CID | Small series | (35) |
| CD40 | Table 1 | CID | | |
| CD40LG | Table 1 | CID | | |
| IPEX (FOXP3), IL2RA (CD25), IL10, IL10R1, IL10R2, CTLA4, LRBA | Table 4 | See dedicated section | | |
| PIK3CD (GOF), PIK3R1 (LOF) | Table 3 | CID with immune-dysregulation, auto-immunity | Small series | (36) |

ID, immunodeficiencies; CID, combined immunodeficiencies; SCID, severe combined immunodeficiencies. Table 1: ID affecting cellular and humoral immunity; Table 2: CID with associated or syndromic features; Table 3: Predominantly antibody deficiencies; Table 4: Diseases of immune dysregulation (susceptibility to EBV and lymphoproliferative conditions).

The donor availability needs also to be considered for the transplant decision. Whatever the diagnosis, HSCT from a healthy matched sibling donor (MSD) remains the gold standard that offers the best results and allows to consider HSCT early in the course of the disease, even pre-emptively if poor outcome is predictable (38) [see reviews on Hematopoietic stem cell transplantation for WAS and DOCK8 deficiency (26) and for MHC class II expression deficiency]. Outcomes obtained with matched unrelated donors (MUD) have increasingly improved in the last decade and are approaching similar survival rates as with MSD [albeit with higher rate of HSCT-related complications (41)] [see review on Hematopoietic stem cell transplantation for WAS and DOCK8 deficiency (26)], allowing extended indications. In the absence of a matched-donor, decision to transplant needs to be balanced. Transplantation from an alternative donor is more challenging even though most recent results show increasingly successful survival, allowing to consider transplant early in the disease course (43–46). At the end, the final decision about transplant will depend on a conjunction of factors such as immunological parameters, the severity of past and current clinical manifestations, i.e., severity of infections, autoimmunity, need of immunosuppressive treatment to control the manifestations related to immune dysregulation and donor compatibility. Family history and their experience with the disease will also weight in the final decision.

Pre-HSCT Evaluation

Cautious evaluation by a multi-disciplinary team is important before transplantation. Previous recurrent or chronic infections may have led to severe and irreversible visceral damage, notably lung and liver. Renal impairment can also occur as a consequence of chronic or recurrent anti-infectious treatment or prolonged immunosuppression. Aggressive pre-emptive treatment and control of all treatable pre-existing infections needs to be proposed prior HSCT. Special attention to detect emergence of antimicrobial drug resistance need to be given, especially in heavily pre-treated patients. In case of EBV-related lymphoproliferation prior to HSCT, the degree of remission required before transplant is a question of debate (47). Optimization of nutritional status is also important. Remission of pre-existing autoimmunity and/or inflammatory conditions should as much as possible be obtained before transplantation, while avoiding prolonged heavy immunosuppression both before and after HSCT that may increase infectious susceptibility.
Conditioning Regimen and GVHD Prophylaxis

The residual T-cell immunity and the intact hematopoiesis of these patients increases the risk of allograft rejection, particularly in case of HLA disparity between donor and recipient. Some degree of myeloablation is usually required. Development of reduced toxicity conditioning regimens (CR) has contributed to reduce transplant-related mortality (TRM) in the last decade (48, 49). Currently, the most frequent associations proposed from the more myeloablative to the more reduced intensity are busulfan/fludarabine, treosulfan/fludarabine, and fludarabine/melphalan. In the absence of organ damage, myeloablative conditioning (MAC) is preferred, while reduced intensity conditioning (RIC) will be considered in case of pre-HSCT co-morbidities. Addition of tiothepa to treosulfan/fludarabine can be discussed in case of mismatched transplant, especially if an ex vivo manipulation of the graft is proposed. Addition of serotherapy (anti-thymocytes globulins or alemtuzumab) is frequently recommended to prevent rejection and GVHD, but its omission can be discussed in HSCT from a MSD. In case of pre-HSCT autoimmunity, treatment with anti-CD20 monoclonal antibodies can be proposed.

Full donor chimerism in all lineages is not always mandatory to correct the underlying disease with exceptions such as WAS, where mixed chimerism has been related to inferior long-term outcome (autoimmunity and thrombocytopenia) (45, 50).

The risk of occurrence of graft-vs.-host-disease (GVHD) is dependent on the degree of compatibility between donor and recipient, but also on the clinical conditions of the recipient. Pre-existing viral infections or inflammation related to autoimmunity or immune dysregulation can predispose to onset of early and severe acute GVHD and therefore, effective GVHD prophylaxis is of primary importance. If GVHD occurs, it needs to be aggressively and rapidly treated.

Donor Choice

HSCT from a geno-identical healthy sibling remains the best option, but available in fewer than 25% of cases. A suitable MUD will be available in ~70% of the remaining options, or even less for patients belonging to ethnic groups insufficiently represented in donor registries (51). Options will be HSCT from an alternative donor, i.e., unrelated mismatched cord-blood (MMCB), mismatched unrelated donor (MMUD), or HLA-haploidentical mismatched family donor (MMFD). In MMUD and MMFD, different types of graft manipulations have been developed to reduce risks of GVHD and graft rejection (52). Historically, CD34+ cell selection was the most commonly used technique, but non-engraftment and slow immune reconstitution limited its applications especially in CIDs. New strategies with selective depletions as CD3/CD19 or TCRalpha/beta and CD19 depletions are increasingly used, limiting the risk of GVHD and allowing good engraftment rate, as long as a myeloablative conditioning (MAC) is administered (53, 54). However, poor early immune reconstitution might still be problematic notably in patients with active infection at the time of HSCT. Haplo-HSCT strategies without ex vivo graft manipulation, but using post-transplant cyclophosphamide (PTCY) as GVHD prophylaxis, have been increasingly used to treat adult patients with malignant diseases. Data on PTCY in children with PIDS and CIDs are still limited but encouraging (43, 44). All these alternative approaches need to be prospectively compared in the context of CIDs.

In conclusion, early molecular diagnosis to facilitate early decision of transplantation before development of co-morbidities, tailoring conditioning regimen to reduce toxicity, improving GVHD prophylaxis and kinetics of immune reconstitution while improving supportive care, are future perspectives that should contribute to improvement of HSCT results in CIDs.

THE EXAMPLE OF CD40L DEFICIENCY: HSCT VS. LONG-TERM SUPPORTIVE TREATMENT

CD40 ligand (CD40L) deficiency (55, 56) is a X-linked disease related to hemizygous mutations in CD40LG gene, encoding CD40L, a glycoprotein (5, 57–61) mainly involved in co-stimulatory T-lymphocyte function. Impaired CD40L expression alters B-cell isotype switching and antibody production, dendritic cell signaling, and myeloid cell function and development (62, 63). Generally, disease onset occurs during early childhood, with frequent respiratory tract infections, diarrhea and neutropenia. As a consequence of chronic cryptosporidial infection, severe biliary tract disease may develop and evolve to sclerosing cholangitis.

CD40L deficiency is associated with high morbidity and mortality. Historically, long-term survival has been poor with supportive therapy only, with 20–50% of patients reaching their thirties (64–66) and only sporadic observations of long-term survivors (67, 68). A median survival of 25 years from diagnosis has been recently shown in 109 patients treated with conservative therapy only (67). This approach currently includes immunoglobulin replacement (IgR), antimicrobial prophylaxis, close monitoring for complications, and careful precautions to avoid Cryptosporidium species exposure. Liver disease is the most significant predictor of mortality (67, 69) and, together with severe infections, represents the major cause of death (64).

At present, HSCT represents the only curative treatment for this disease. Historically, its outcome has not been optimal (65). In a first European retrospective survey (70), overall survival (OS) after HSCT was 68% and transplant was curative in only 58% of patients, most of whom without liver disease. More recently, the multi-center retrospective observational study of la Morena et al. showed similar OS between patients with CD40L deficiency treated with or without HSCT, but among survivors, transplanted patients showed higher median age performance status scores and greater well-being, as compared to non-transplanted patients (67). In addition, a survival improvement for transplanted patients was progressively observed since 1987,
suggesting better transplant practices in more recent years (67). This positive trend was confirmed by a recent Japanese study (71), reporting improved outcome in 29 patients undergoing HSCT, and also by a subsequent international retrospective survey (42), in which HSCT outcome was analyzed in 130 patients with CD40L deficiency transplanted between 1993 and 2015. In this study, OS, event-free (EFS) and disease-free survival (DFS) 5 years post-HSCT were 78.2, 58.1, and 72.3%, respectively. A general HSCT outcome improvement was confirmed after 2000, mainly thanks to amelioration of transplant-related procedures, earlier age at transplantation, and lower organ damage burden, especially liver disease. Indeed, after 2000, best results were obtained in children transplanted before 5 years, while organ damage before HSCT was confirmed to negatively influence outcome (42). Superior OS was achieved with matched donors, both MSD and MUD. Myeloablation resulted in better OS and DFS, as compared to RIC. Moreover, MAC was associated with higher EFS. Among survivors who could stop IgR, T-lymphocyte chimerism was mainly donor in most. However, decreasing lineage-specific chimerism was observed in some transplants, underlying the problem of residual host immunity. In line with this, myeloablation seemed to be required to attain complete engraftment. Indeed, RIC and non-myeloablative conditioning resulted associated with poor or absent engraftment.

Interestingly, de la Morena et al. (67) evidenced geographic differences in HSCT practices: indication for HSCT was variable, with higher transplant rates in European centers as compared to American ones. This is a reflection of the still unsolved debate about the best management of these patients. Guidelines were proposed by the European Society for Blood and Marrow Transplantation/European Society for Immunodeficiencies Inborn Errors Working Party in 2011 (72). These recommendations favored HSCT at diagnosis in case of MSD availability, HSCT at early complication development in case of MUD or MMUD, and later, salvage HSCT in case of progressive organ damage for those with MMFD available only. However, recently published data prompt an update of these guidelines, suggesting that HSCT can cure CD40L deficiency, but its outcome is better if it is performed upfront, before the development of organ damage, and using MAC, which associated with higher survival and cure rate. In addition, it was recently shown (73) that an effective early HSCT can also improve or even reverse mild to moderate chronic cholangiopathy, presumably thanks to the clearance of chronic infections after immune reconstitution. Nevertheless, in spite of recent outcome amelioration, HSCT still remains a risky therapeutic option for older patients, for those with organ damage, especially severe liver disease, and/or for those with limited donor availability. For these patients, gene editing may represent an attractive potential alternative treatment, since infusion of gene-corrected T-lymphocytes or HSC may be curative (74, 75) [see review on “Autologous stem cell-based gene therapy for inherited disorders: state-of-the-art and future prospects” (76)]. Finally, prospective studies are needed to perform comparative analyses about the risks of HSCT and those of life-long supportive therapy, including quality of life measures. Detailed longitudinal clinical data are lacking, especially regarding infection-related burden in terms of frequency of hospital admissions or missed days of school/work. These are fundamental to standardize patients’ management aimed not only at improving survival, but also at optimizing quality of life.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**REFERENCES**

1. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. *Nat Rev Dis Prim.* (2015) 1:15061. doi: 10.1038/nrdp.2015.61
2. Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. *J Allergy Clin Immunol.* (2017) 140:1388–1393.e8. doi: 10.1016/j.jaci.2016.12.978
3. Buchbinder D, Hauck F, Albert MH, Rack A, Bakhtiar S, Shcherbina A, et al. Rubella virus-associated cutaneous granulomatous disease: a unique complication in immune-deficient patients, not limited to DNA repair disorders. *J Clin Immunol.* (2019) 39:81–9. doi: 10.1007/s10875-018-0581-0
4. Bomken S, van der Werff Ten Bosch J, Attarbaschi A, Bacon CM, Bokhjardt A, Boztug K, et al. Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders: the perspective of an interdisciplinary working group. *Front Immunol.* (2018) 9:2912. doi: 10.3389/fimmu.2018.02912
5. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. *J Clin Immunol.* (2018) 38:96–128. doi: 10.1007/s10875-017-0464-9
6. ESIDRegistry_ClinicalCriteria. Available online at: https://esid.org/Working-Parties/Registry-Working-Party/Diagnosis-criteria

7. John T, Walter J, Schuetz C, Chen K, Abraham R, Bonfim C, et al. Unrelated hematopoietic cell transplantation in a patient with combined immunodeficiency with granulomatous disease and autoimmune secondary to RAG deficiency. *J Clin Immunol.* (2016) 36:725–32. doi: 10.1007/s10875-016-0326-x
8. Stepsens P, Keller B, Shamriz O, von Spee-Mayer C, Friedmann D, Shadur B, et al. T+ NK+ IL-2 receptor γ chain mutation: a challenging diagnosis of atypical severe combined immunodeficiency. *J Clin Immunol.* (2018) 38:527–36. doi: 10.1007/s10875-018-0514-y
9. Farnault L, Chambost H, Michel G, Thuret I, de Saint Basile G, Fischer A, et al. Persistence of natural killer cells with expansion of a hypofunctional NK+γ- chain subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency. *J Allergy Clin Immunol.* (2013) 131:1230–3. doi: 10.1016/j.jaci.2012.08.047
10. Gao Y, Arkwright PD, Carter R, Cazaly A, Harrison RJ, Mant A, et al. Bone marrow transplantation for MHC class I deficiency corrects T-cell immunity secondary to RAG deficiency. *J Clin Immunol.* (2016) 138:1733–6. doi: 10.1007/s10875-016-0629
11. Ozgürl T, Asal G, Cetinkaya D, Orhan D, Kılıç S, Usta Y, et al. Persistence of natural killer cells with expansion of a hypofunctional NK+γ- chain subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency. *J Allergy Clin Immunol.* (2013) 131:1230–3. doi: 10.1016/j.jaci.2012.08.047
12. Morgan N, Goddard S, Cardno T, McDonald D, Rahman F, Barge D, et al. Mutation in the TCRα subunit constant gene (TRA) leads to a human
immunodeficiency disorder characterized by a lack of TCR
immunodeficiency and autoimmunity. J Allergy Clin Immunol.
(2016) 36:713–24. doi: 10.1016/j.jaci.2016.03.016-e
14. Ghosh S, Drexler I, Bhata S, Gennero AR, Borkhardt A. Interleukin-2-
inducible T-cell kinase deficiency–new patients, new insight? Front Immunol.
(2018) 9:979. doi: 10.3389/fimmu.2018.00979
15. Hauck F, Randriamampita C, Martin E, Gerart S, Lambert N, Lim A, et al. Primary T-cell immunodeficiency with immunoregulatory causation
by autosomal recessive LCK deficiency. J Allergy Clin Immunol. (2012) 130:1144–
52.e11. doi: 10.1016/j.jaci.2012.07.029
16. Keller B, Zaidman I, Yousefi O, Hershkovitz D, Stein J, Unger S, et al. Early onset combined immunodeficiency and autoimmune in patients with loss-of-function mutation in LAT. J Exp Med. (2016) 213:1185–99. doi: 10.1084/jem.20151110
17. Crequer A, Troeger A, Patin E, Ma C, Picard C, Pedergnana V, et al. Human RH0H deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Immunol. (2012) 122:3239–47. doi: 10.1172/JCI62949
18. Picard C, McCarl C, Papolos A, Khail S, Lüthy K, Hivroz C, et al. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmune. N Engl J Med. (2009) 360:1971–80. doi: 10.1056/NEJMoa0900882
19. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel S, Tanasa B, et al. A mutation in Orail causes immune deficiency by aborting CRAC channel function. Nature. (2006) 441:179–85. doi: 10.1038/nature04702
20. Lian J, Cuk M, Kahlfuss S, Kozhaya L, Vaeth M, Rieux-Laucat F, et al. ORAI1 mutations abolishing store-operated Ca2+-entry cause autonomic ectodermal dysplasia with immunodeficiency. J Allergy Clin Immunol. (2018) 142:1297–310.e11. doi: 10.1016/j.jaci.2017.10.031
21. Miot C, Imai K, Imai C, Mancini A, Kucuk Z, Kawai T, et al. Hematopoietic stem cell transplantation in 29 patients hemzygous for hypomorphic IL7RB/NEMO mutations. Blood. (2017) 130:1456–67. doi: 10.1182/blood-2017-03-771600
22. Boisson B, Puel A, Picard C, Casanova J. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Immunol. (2012) 122:3239–47. doi: 10.1172/JCI62949
23. Turvey S, Durandy A, Fischer A, Fung S, Geha R, Gewies A, et al. The CARDI1-BCL10-MAIT1 (CBM) signalsome complex: coming into the limelight of human primary immunodeficiency. J Allergy Clin Immunol. (2014) 134:276–84. doi: 10.1016/j.jaci.2014.04.015
24. Willmann K, Klaver S, Dogu F, Santos-Valente E, Garnarw C, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Immun. (2014) 19:5360. doi: 10.1038/ncomms9360
25. Nademi Z, Wynn R, Slater M, Hughes S, Donney D, Qasim W, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol Pract. (2019) 7:848–55. doi: 10.1016/j.jaip.2018.10.035
26. Ferrari F, Galimberti S, Courtelie V, Dvorak CC, Neven B, Fischer A, et al. Hematopoietic stem cell transplantation for patients with activated PI3K delta syndrome. J Allergy Clin Immunol. (2017) 139:1046–9. doi: 10.1016/j.jaci.2016.09.040
27. Malhauoi N, Picard C, Bach PB, Costes LB, Courtelie VB, Nanohapvimparany A, et al. Genetic diagnosis of primary immunodeficiencies: a survey of the French national registry. J Allergy Clin Immunol. (2019) 143:1646–1649.e10. doi: 10.1016/j.jaci.2018.12.994
28. Gennery AR, Slater MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for Primary immunodeficiency disorders in Europe: entering a new century, do we do better? J Allergy Clin Immunol. (2010) 126:602–10.e11. doi: 10.1016/j.jaci.2010.06.015
29. Speckmann G, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, et al. A prospective study on the natural history of patients with profound combined immunodeficiency: an interim analysis. J Allergy Clin Immunol. (2017) 139:1302–1310.e4. doi: 10.1016/j.jaci.2016.07.040
30. Klein C, Cavazzana-Calvo M, Le Deist F, Jabado N, Benkerrou M, Blanche S, et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood. (1995) 85:580–70. doi: 10.1182/blood.V85.2.580.580
31. Aydin SE, Freeman AF, Al-Herz W, Al-Mousa HA, Arnaout RK, Aydin RC, et al. Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency. J Allergy Clin Immunol Pract. (2019) 7:848–55. doi: 10.1016/j.jaip.2018.09.007
32. Ferrua F, Galimberti S, Courtelie V, Slater MA, Booth C, Moshous D, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. (2019) 143:2238–53. doi: 10.1016/j.jaci.2018.12.1010
33. Neven B, Diana JS, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children, biol blood marrow transplant. (2019) 25:1363–73. doi: 10.1016/j.bbmt.2019.03.009
34. Kurzay M, Hauck F, Schmid I, Wiebking V, Eichinger A, Jung E, et al. T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. Haematologica. (2010) 104:e78–82. doi: 10.3324/haematol.2018.215285
35. Elifey R, Furtado-Silva J, Chiesa R, Tao K, Amrolia P, Lucchini G, et al. One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. J Allergy Clin Immunol. (2018) 142:1654–6.6.e7. doi: 10.1016/j.jaci.2018.06.042
36. Balashov D, Laberko A, Scherbina A, Traktman P, Abramov D, Gutovskaya E, et al. A conditioning regimen with plerixafor is safe and improves the outcome of TCRβ- and CD19+ Cell-depleted stem cell transplantation in patients with wiskott-aldrich syndrome. Biol Blood Marrow Transpl. (2018) 24:1432–40. doi: 10.1016/j.bbmt.2018.03.006
47. Cohen JM, Sebire NJ, Harvey J, Gaspar HB, Cathy C, Jones A, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood. (2007) 110:2209-14. doi: 10.1182/blood-2006-12-062174

48. Worth AJ, Booth C, Veys P. Stem cell transplantation for primary immune deficiency. Curr Opin Hematol. (2013) 20:501-8. doi: 10.1097/MOH.0b013e328365a13b

49. Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al. TREsulfan and fudarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. (2018) 24:529–36. doi: 10.1016/j.bbmt.2017.11.009

50. Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood. (2011) 118:1675–84. doi: 10.1182/blood-2010-11-319376

51. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitby R, et al. HLA Match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. (2014) 371:339–87. doi: 10.1056/NEJMsa1311707

52. Locatelli F, Vinti L, Palumbo G, Rossi F, Bertaina A, Mastronuzzi A, et al. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Pract Res Clin Haematol. (2011) 24:339–49. doi: 10.1016/j.beha.2011.04.004

53. Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor αβ+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. (2018) 141:1417–26.e1. doi: 10.1016/j.jaci.2017.07.008

54. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ and B cells in children with nonmalignant disorders. Blood. (2014) 124:822–6. doi: 10.1182/blood-2014-03-563817

55. DiSanto JP, Bonnefoy Y, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature. (1993) 361:541–3. doi: 10.1038/361541a0

56. Notarangelo LD, Petitsch MC, Abrahamsen TG, Belfort C, Bordignon P, Cant AJ, et al. CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Rev. (1994) 138:39–59. doi: 10.1111/j.1600-065X.1994.tb00846.x

57. Allen R, Armitage R, Conley M, Rosenblatt H, Jenkins N, Copeland N, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. (1993) 259:990–3. doi: 10.1126/science.7679801

58. Korthäuer U, Graf D, Brugnoni D, Giliani S, Korthüer U, Ugazio A, et al. Defective expression of CD40 ligand on T cells causes “X-linked hyper-IgM syndrome.” J Immunol. (1994) 153:1018–24. doi: 10.1165/1994.JCI16984

59. Cabral-Marques O, Al-Sbiei A, Khan TA, Feriotti C, et al. CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-γ. J Allergy Clin Immunol. (2017) 139:900–12. doi: 10.1016/j.jaci.2016.07.018

60. Crozcek RA, Brugnoni D, Giliani S, Korthüer U, Ugazio A, et al. Defective expression of CD40 ligand on T cells causes “X-linked hyper-IgM syndrome (HIGM1).” Immunol Rev. (1994) 138:39–59. doi: 10.1111/j.1600-065X.1994.tb00846.x

61. Kuo CY, Long JD, Campo-Fernandez B, de Oliveira S, Cooper AR, et al. Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper-IgM but can be prevented by early hematopoietic stem cell transplantation. J Allergy Clin Immunol. (2018) 141:405–8.e7. doi: 10.1016/j.jaci.2017.06.036

62. Ferrua HSCT in CID and CD40L Deficiency. Front Pediatr. (2019). Available online at: https://esid.org/layout/set/print/Working-Parties/Inborn-Errors-Working-PartyIEWP/Resources/UPDATED--EBMT-ESID-GUIDELINES-FOR-HAEMATOPOIETIC-STEM-CELL-TRANSPLANTATION-FOR-PI

63. Hadžić N, Nademi Z, Deheragoda M, Zen Y, Elfeky R, Worth A, et al. Chronic cholangiopathy associated with primary immune deficiencies can be resolved by effective hematopoietic stem cell transplantation. J Pediatr. (2019) 209:97–106.e2. doi: 10.1016/j.jpeds.2019.01.015

64. Kuo CY, Long JD, Campo-Fernandez B, de Oliveira S, Cooper AR, Romero Z, et al. Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. Cell Rep. (2018) 23:2606–16. doi: 10.1016/j.celrep.2018.04.103

65. Staal FJT, Aiuti A, Cavazzana M. Autologous stem-cell-based gene therapy for hematopoietic cell transplantation. Blood. (2016) 127:2513–23. doi: 10.1182/blood-2015-11-683235

66. Rezaei N, Notarangelo LD. Hematopoietic stem cell transplantation for hyper-IgM syndromes. Pediatr Transplant. (2013) 17:1–2. doi: 10.1111/petr.12012

67. Cabral-Marques O, Ramos RN, Schimke LF, Khan TA, Amiral EP, Barbosa Bomfim CC, et al. Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-γ. J Allergy Clin Immunol. (2017) 139:900–12. doi: 10.1016/j.jaci.2016.07.018

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.